Asuragen and Thermo Fisher Scientific to Collaborate on Diagnostic Kits for 3500 Dx Series Genetic Analyzer

AUSTIN, Texas − February 20, 2017 − Asuragen, Inc., a global molecular diagnostics company, announced today that it has entered into a collaboration agreement with Thermo Fisher Scientific for the development and commercialization of capillary electrophoresis-based in vitro diagnostics (IVDs).

Asuragen will leverage its AmplideX® PCR/CE product technologies to develop diagnostic kits for the 3500 Dx Series Genetic Analyzer CS2 instrument. Asuragen’s kits for PCR/CE provide unparalleled performance for analyzing repetitive sequences. In addition, they integrate Asuragen’s analytics and reporting suite, the AmplideX® Reporter, providing a straightforward sample-to-answer solution.

“More than half the genome is made up of repetitive sequences and short structural variations that are not well served by current diagnostic technologies, including next generation sequencing. The combination of Thermo Fisher’s capillary electrophoresis instruments’ performance and our novel AmplideX chemistries provides the level of resolution required for these emerging biomarkers,” said Matt McManus, MD, PhD, President and CEO of Asuragen. “Our AmplideX PCR/CE products are built under design control and manufactured in our cGMP facility, providing the high quality required for IVD products.”

“We welcome the opportunity to collaborate with Asuragen to expand the diagnostic products for our 3500 Dx Genetic Analyzer platform,” said Kim Kelderman, Vice President and General Manager for the Genetic Analysis Business at Thermo Fisher Scientific. “Asuragen is recognized for delivering high performance and quality molecular diagnostic products in the fields of genetics and oncology. We look forward to working with them on products serving significant clinical needs.”

About Asuragen
Asuragen is a global diagnostic products company delivering solutions that build knowledge and understanding of complex clinical questions. Asuragen’s application of its deep scientific heritage and molecular expertise delivers diagnostic products in oncology and genetics that provide the best answers with optimal workflows – so time can be spent delivering actionable insights, rather than searching for them. With innovative approaches to kit development and a broad range of molecular chemistries, Asuragen produces assays that ensure reproducible results. From discovery and development to regulatory support to global commercialization, we also provide a tailored approach that efficiently delivers custom and companion diagnostic products for our partners. We believe people deserve better answers. For more information, visit www.asuragen.com.

Contact:
Lynne Hohlfeld
Asuragen, Inc.
SVP, Corporate Development and CFO
PH: 512.681.5200
lhohlfeld@asuragen.com
www.asuragen.com

February 20th, 2017|News|